X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Learning from history: How government price setting and other anti-innovation policies negatively impact biopharmaceutical R&D

By Nicole Longo  |    November 16, 2020
Today, America leads the world in medical innovation because of our unique research ecosystem, but that wasn’t always the case. A new paper from NDP Analytics, “Will US Leadership in...   Read More

ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19

By Andrew Powaleny  |    August 4, 2020
America’s biopharmaceutical companies are working around the clock to defeat COVID-19, a disease caused by a novel strain of the coronavirus. The biopharmaceutical industry continues to make...   Read More

Executive order threatens R&D when we need it most to fight COVID-19

By Nicole Longo  |    July 30, 2020
In case you missed it, President Trump recently signed executive orders that would implement sweeping changes to the biopharmaceutical industry. While his intention may have been to help Americans...   Read More

The continued imperative to protect U.S. innovation worldwide

By Chris Moore  |    April 29, 2020
The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are...   Read More

Three reasons the Administration should abandon its International Pricing Index proposal

By Nicole Longo  |    January 31, 2020
According to the Council of Economic Advisers, “Heavy-handed government intervention may reduce drug prices in the short term, but these savings are not worth the long-term cost of American...   Read More

Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important

By Guest Contributor  |    September 4, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Setting the record straight on international reference pricing

By Kevin Haninger  |    July 16, 2019
There’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability...   Read More

By the numbers: A look at the Part B International Pricing Index Model

By Nicole Longo  |    June 6, 2019
Mounting research continues to point to how international reference pricing schemes, like the Department of Health and Human Services’ (HHS) International Pricing Index (IPI) Model, could result...   Read More

Fact Check: How the Part B International Pricing Index Model replaces market competition with government-set prices

By Nicole Longo  |    May 3, 2019
One of the most common misconceptions about the administration’s proposed Part B International Pricing Index (IPI) Model is that it would improve competition in Medicare. However, mounting...   Read More

Fact Check: How the Part B International Pricing Index model threatens patient access

By Nicole Longo  |    March 29, 2019
Since the Department of Health and Human Services (HHS) released the Part B International Pricing Index (IPI) model late last year, there have been a number of inaccurate claims floating around...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates